Moreover, Vetter et al. have recently described a significant reduction of circulating tumor cell (CTC) count in advanced BC patients receiving denosumab compared to those who did not receive the anti-RANK-L antibody (p = 0.03), suggesting a potential inhibitory effect of this agent against tumor cell intravasation [55]. Here, TNFSF11 is linked to breast cancer.